Acetylcholine

Basic Neurochemistry

Volumn , Issue , 2012, Pages 258-282

  Fisher, Stephen K ^a   Wonnacott, Susan ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882500442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374947-5.00013-4     Document Type: Chapter

References (72)

1. Adams J.P., Sweatt J.D. Molecular psychology: Roles for the ERK MAPK cascade in memory. Annual Review of Pharmacology and Toxicology 2002, 42:135-163.
2. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rhanama N.P., Nathanson N.M., et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic mutant mice. Nature Neuroscience 2003, 6:51-58.
3. Apparsundaram S., Martinez V., Parikh V., Kozak R., Sarter M. Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. Journal of Neuroscience 2005, 25:3851-3856.
4. Badio B., Daly J.W. Epibatidine, a potent analgesic and nicotinic agonist. Molecular Pharmacology 1994, 45:563-569.
5. Bazalakova M.H., Blakely R.D. The high-affinity choline transporter: A critical protein for sustaining cholinergic signaling as revealed in studies of genetically altered mice. Handbook of Experimental Pharmacology 2006, 175:525-544.
6. Bierut L.J. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends in Pharmacological Sciences 2010, 31:46-51.
7. Bierut L.J., Stitzel J.A., Wang J.C., Hinrichs A.L., Grucza R.A., Xuei X., et al. Variants in nicotinic receptors and risk for nicotine dependence. The American Journal of Psychiatry 2008, 165:1163-1171.
8. Birdsall N.J.M., Burgen A.S.V., Hulme E.C. The binding of agonists to brain muscarinic receptors. Molecular Pharmacology 1978, 14:723-736.
9. Bordia T., Campos C., Huang L., Quik M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 2008, 327:239-247.
10. Bowman W.C. Neuromuscular block. British Journal of Pharmacology 2006, 147(Suppl. 1):S277-286.
11. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van Der Oost J., Smit A.B., et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411:269-276.
12. Celie P.H., van Rossum-Fikkert S.E., van Dijk W.J., Brejc K., Smit A.B., Sixma T.K. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004, 41:907-914.
13. Champtiaux N., Changeux J.P. Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Acetylcholine in the Cerebral Cortex 2004, 145:235-251.
14. Changeux J.P. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nature Reviews Neuroscience 2010, 11:389-401.
15. Changeux J.P., Devillers-Thiéry A., Chemouilli P. Acetylcholine receptor: An allosteric protein. Science 1984, 225:1335-1345.
16. Colquhoun D., Ogden D.C., Mathie A. Nicotinic acetylcholine receptors of nerve and muscle: Functional aspects. Trends in Pharmacological Sciences 1987, 8:465-472.
17. Conn P.J., Jones C.K., Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacological Sciences 2009, 30:148-155.
18. Cossins J., Webster R., Maxwell S., Burke G., Vincent A., Beeson D. A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Human Molecular Genetics 2004, 13:2947-2957.
19. Dale H.H. The action of certain esters and ethers of choline, and their relation to muscarine. Journal of Pharmacology and Experimental Therapeutics 1914, 6:147-190.
20. Dale H.H., Dudley H.W. The presence of histamine and acetylcholine in the spleen of the ox and the horse. Journal of Physiology 1929, 68:97-123.
21. Dale, H. H., Feldberg, W., & Vogt, Release of acetylcholine at voluntary motor nerve endings. The Journal of Physiology (London), 86, 353-380.
22. Dajas-Bailador F., Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends in Pharmacological Sciences 2004, 25:317-324.
23. Duttaroy A., Gomeza J., Gan J.W., Siddiqui N., Basile A.S., Harman W.D., et al. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Molecular Pharmacology 2002, 62:1084-1093.
24. Ferguson S.M., Blakely R.D. The choline transporter resurfaces: New roles for synaptic vesicles?. Molecular Interventions 2004, 4:22-37.
25. Fisher S.K. Inositol lipids and signal transduction at CNS muscarinic receptors. Trends in Pharmacological Sciences Supplement: Subtypes of Muscarinic Receptors II 1986, 61-65.
26. Forster G.L., Yeomans J.S., Takeuchi J., Blaha C.D. M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. Journal of Neuroscience 2001, 21(RC 190):1-6.
27. Govind A.P., Vezina P., Green W.N. Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine addiction. Biochemical Pharmacology 2009, 78:756-765.
28. Grønlien J.H., Håkerud M., Ween H., Thorin-Hagene K., Briggs C.A., Gopalakrishnan M., et al. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Molecular Pharmacology 2007, 72:715-724.
29. Hasselmo M.E., Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2010, (Epub ahead of print).
30. Johnson G., Swart C., Moore S.W. Interaction of acetylcholinesterase with the G4 domain of the laminin alpha1-chain. Biochemical Journal 2008, 411:507-514.
31. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nature Reviews Neuroscience 2002, 3:102-114.
32. Kubo T., Fukuda K., Mikami A., Maeda A., Takahashi H., Mishina M., et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323:411-416.
33. Kuryatov A., Onksen J., Lindstrom J. Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Molecular Pharmacology 2008, 74:132-143.
34. Langley J.N. On nerve endings and on special excitable substances in cells. Proceedings of the Royal Society of London. Series B 1906, 78:170-194.
35. Langmead C.J., Watson J., Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacology & Therapeutics 2008, 117:232-243.
36. Le Novère N., Changeux J.P. Molecular evolution of the nicotinic acetylcholine receptor: An example of multigene family in excitable cells. Journal of Molecular Evolution 1995, 40:155-172.
37. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: Evidence for self medication. Journal of Dual Diagnosis 2007, 3:43-59.
38. Liao D.L., Hong C.J., Chen Y.E., Lee S.M., Chang C.Y. Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003, 48(2):72-76.
39. Lindstrom J. Autoimmune diseases involving nicotinic receptors. Journal of Neurobiology 2002, 53:656-665.
40. Loewi O. Ueber humorale Uebertragbarkeit der herznervenwirkung. Pfluegers Archiv General Physiology 1921, 189:239-242.
41. Liu Z., Zhang J., Berg D.K. Role of endogenous nicotinic signaling in guiding neuronal development. Biochemical Pharmacology 2007, 74:1112-1119.
42. Livingstone P.D., Wonnacott S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochemical Pharmacology 2009, 78:744-755.
43. Maehle A.H., Prüll C.R., Halliwell R.F. The emergence of the drug receptor theory. Nature Reviews Drug Discovery 2002, 1:637-641.
44. Massoulié J., Millard C.B. Cholinesterases and the basal lamina at vertebrate neuromuscular junctions. Current Opinion in Pharmacology 2009, 9:316-325.
45. Massoulié J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002, 11:130-143.
46. McIntosh J.M., Absalom N., Chebib M., Elgoyhen A.B., Vincler M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochemical Pharmacology 2009, 78:693-702.
47. Millar N.S., Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56:237-246.
48. Murrin L.C., Kuhar M.J. Activation of high affinity choline uptake in vitro by depolarizing agents. Molecular Pharmacology 1976, 12:1082-1090.
49. Okuda T., Haga T., Kanai Y., Endou H., Ishihara T., Katsura I. Identification and characterization of the high affinity choline transporter. Nature Neuroscience 2000, 3:120-125.
50. Paton W.D., Zaimis E.J. The pharmacological actions of polymethylene bistrimethylammonium salts. British Journal of Pharmacology 1949, 120(Suppl. 1997):60-79.
51. Perrier A.L., Massoulié J., Krejci E. PRiMA: The membrane anchor of acetylcholinesterase in the brain. Neuron 2002, 33:275-285.
52. Picciotto M.R., Zoli M., Rimondini R., Léna C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
53. Picciotto M.R., Alreja M., Jentsch D. Acetylcholine. Neuropsychopharmacology: The fifth generation of progress 2002, 1-14. Amer. Coll. of Neuropsychopharmacology, Brentwood, TN. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
54. Quik M., O'Neill M., Perez X.A. Nicotine neuroprotection against nigrostriatal damage: Importance of the animal model. Trends in Pharmacological Sciences 2007, 28:229-235.
55. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends in Pharmacological Sciences 2007, 28:316-325.
56. Seeger T., Fedorova I., Zheng F., Miyakawa T., Koustova E., Gomeza J., et al. M2 muscarinic acetylcholine knock-out mice show deficits in behavioral flexibility, working memory and hippocampal plasticity. Journal of Neuroscience 2004, 24:10117-10127.
57. Silman I., Sussman J.L. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Current Opinion in Pharmacology 2005, 5:293-302.
58. Silman I., Sussman J.L. Acetylcholinesterase: How is structure related to function?. Chemico-Biological Interactions 2008, 175:3-10.
59. Sine S.M., Engel A.G. Recent advances in Cys-loop receptor structure and function. Nature 2006, 440:448-455.
60. Soreq H., Seidman S. Acetylcholinesterase-new roles for an old actor. Nature Reviews Neuroscience 2001, 2:294-302.
61. Steinlein O.K., Bertrand D. Neuronal nicotinic acetylcholine receptors: From the genetic analysis to neurological diseases. Biochemical Pharmacology 2008, 76:1175-1183.
62. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., et al. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 1991, 253:872-879.
63. Sussman J.L., Silman I. Acetylcholinesterase: Structure and use as a model for specific cation-protein interactions. Current Opinion in Structural Biology 1992, 2:721-729.
64. Taylor P., Radic Z. The cholinesterases: From genes to proteins. Annual Review of Pharmacology and Toxicology 1994, 34:281-320.
65. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. Journal of Molecular Biology 2005, 346:967-989.
66. Verderio C., Rossetto O., Grumelli C., Frassoni C., Montecucco C., Matteoli M. Entering neurons: Botulinum toxins and synaptic vesicle recycling. Embo Journal 2006, 7:995-999.
67. Vetter D.E., Katz E., Maison S.F., Taranda J., Turcan S., Ballestero J., et al. The alpha10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20594-20599.
68. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crc Critical Reviews in Clinical Neurobiology 1996, 10:69-99.
69. Wess J., Eglen R.M., Gautam D. Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. Nature Reviews Drug Discovery 2007, 6:721-733.
70. Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. British Journal of Pharmacology 2008, 154:1558-1571.
71. Xu W., Gelber S., Orr-Urtreger A., Armstrong D., Lewis R.A., Ou C.N., et al. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5746-5751.
72. Xu W., Orr-Urtreger A., Nigro F., Gelber S., Sutcliffe C.B., Armstrong D., et al. Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. Journal of Neuroscience 1999, 19:9298-9305.